While still modest in absolute scale compared with global leaders, the UK is now one of Europe’s fastest-growing prescription markets, supported by improving clinician familiarity and increasing patient awareness. Private medical cannabis in the UK now sits at the intersection of regulatory reform, patient demand and private healthcare economics. Since rescheduling in 2018, the sector has moved beyond early uncertainty into a designated clinical market with measurable growth. Internationally, however, it sits behind established giants: Germany operates the continent’s largest reimbursed medical programme with broader physician participation; Canada combines a mature medical system with full adult-use legalisation and vertically integrated public companies; and the United States, though federally fragmented, represents…